This April, our partners at Ginkgo Bioworks who recently announced a new project funded through the Advanced Research Projects Agency for Health (ARPA-H) totaling up to $29 million to establish a new manufacturing process for essential medicines using wheat germ cell-free expression systems.
According to the company, utilizing wheat germ, an abundant and renewable resource, could create a new paradigm for domestic manufacturing, stabilizing and reshoring supply chains for essential pharmaceuticals.
The Commonwealth is home to ARPA-H’s Investor Catalyst Hub. Massachusetts-based companies and institutions have been awarded approximately more than $400 million through ARPA-H.
Read more from Ginkgo, whose growth the MLSC has been proud to support through its internship and Tax Incentive programming.
